BridgeBio Pharma (BBIO) Leases (2020 - 2025)
Historic Leases for BridgeBio Pharma (BBIO) over the last 6 years, with Q3 2025 value amounting to $6.6 million.
- BridgeBio Pharma's Leases rose 177.05% to $6.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.6 million, marking a year-over-year increase of 177.05%. This contributed to the annual value of $5.8 million for FY2024, which is 2815.5% down from last year.
- As of Q3 2025, BridgeBio Pharma's Leases stood at $6.6 million, which was up 177.05% from $6.2 million recorded in Q2 2025.
- In the past 5 years, BridgeBio Pharma's Leases ranged from a high of $17.1 million in Q3 2021 and a low of $5.8 million during Q4 2024
- Its 5-year average for Leases is $10.3 million, with a median of $9.8 million in 2023.
- In the last 5 years, BridgeBio Pharma's Leases soared by 7739.53% in 2021 and then tumbled by 3287.23% in 2022.
- Quarter analysis of 5 years shows BridgeBio Pharma's Leases stood at $15.9 million in 2021, then plummeted by 32.87% to $10.7 million in 2022, then fell by 24.83% to $8.0 million in 2023, then fell by 28.15% to $5.8 million in 2024, then increased by 13.63% to $6.6 million in 2025.
- Its Leases stands at $6.6 million for Q3 2025, versus $6.2 million for Q2 2025 and $7.2 million for Q1 2025.